<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02733094</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN547ADE01T</org_study_id>
    <nct_id>NCT02733094</nct_id>
  </id_info>
  <brief_title>Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum</brief_title>
  <official_title>Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the efficacy and safety of anti-Interleukin-(IL)17
      therapy (secukinumab, administered weekly for 4 weeks followed by four-weekly administration
      until week 16) for the treatment of pyoderma gangrenosum.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the Physician's global assessment</measure>
    <time_frame>Week 16</time_frame>
    <description>The primary response parameter change of the physician global assessment (PGA) 5-point scale at week 16 as compared to week 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in surface area of lesions of pyoderma gangrenosum (two-dimensional surface in mm²)</measure>
    <time_frame>Week 2,3,8,16,28,40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of patient's quality of life</measure>
    <time_frame>Week 2, 4, 8, 16, 28, 40</time_frame>
    <description>Patient's quality of life is assessed by the Dermatology Life Quality Index (DLQI) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of serum C reactive protein (mg/dl)</measure>
    <time_frame>Week 2, 4, 8, 16, 28, 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of leukocyte counts (x10.e3/µl)</measure>
    <time_frame>Week 2, 4, 8, 16, 28, 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of blood sedimentation rate (mm/h)</measure>
    <time_frame>Week 2, 4, 8, 16, 28, 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemical analysis of IL-17+ immune cells</measure>
    <time_frame>Week 16</time_frame>
    <description>The number of IL-17+ immune cells is counted in two high-power-fields (400x) and mean in calculated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Pyoderma Gangrenosum</condition>
  <arm_group>
    <arm_group_label>Open-label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 2 weeks until week 32.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <arm_group_label>Open-label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Key Inclusion Criteria:

               -  Confirmed diagnosis of Pyoderma gangrenosum

               -  Biopsy-proven, non-healing ulcer with primarily neutrophil infiltration,
                  regardless of size and location

               -  Characterization of target lesion (size, PGA, duration)

               -  18-75 years of age

               -  Body weight ≥ 40 kg and ≤ 160 kg

               -  Signed informed consent

          -  Key Exclusion Criteria:

               -  Permanent severe diseases, especially those affecting the immune system

               -  Pregnancy or breast feeding

               -  History or presence of epilepsy, significant neurological disorders,
                  cerebrovascular attacks or ischemia

               -  Myocardial infarction or cardiac arrhythmia which requires drug therapy

               -  Evidence of severe renal dysfunction or significant hepatic disease

               -  History of irritable bowel disease

               -  History of lymphoproliferative disorders

               -  Evidence for active infection including but not limited to active tuberculosis,
                  HIV or hepatitis B/C that in the opinion of the investigator would compromise the
                  patient's ability to tolerate therapy

               -  History of malignancy of any organ system, treated or untreated, whether or not
                  there is evidence of local recurrence or metastases, with the exception of
                  localized basal cell carcinoma of the skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kilian Eyerich, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kilian Eyerich, MD, PhD</last_name>
    <email>kilian.eyerich@tum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felix Lauffer, MD</last_name>
    <email>felix.lauffer@tum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Technical University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kilian Eyerich, MD, PhD</last_name>
      <email>kilian.eyerich@tum.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyoderma</mesh_term>
    <mesh_term>Pyoderma Gangrenosum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

